TCR2 Therapeutics (TCRR) Stock Price, News & Analysis

Company Overview

TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It is also involved in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle on May 29, 2015 and is headquartered in Cambridge, MA.

Key Stats

• Today's Range: $1.48 to $1.48
• 50-Day Range: $1.48 to $1.98
• 52-Week Range: $0.82 to $3.88
• Volume: N/A
• Average Volume: 494,777 shs
• Market Capitalization: $58.10 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TCRR Stock Analysis - Frequently Asked Questions

How were TCR2 Therapeutics' earnings last quarter?

TCR2 Therapeutics Inc. (NASDAQ:TCRR) released its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.63) by $0.06.

When did TCR2 Therapeutics IPO?

TCR2 Therapeutics (TCRR) raised $76 million in an initial public offering (IPO) on Thursday, February 14th 2019. The company issued 5,000,000 shares at $14.55-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and China Renaissance were co-managers.

What other stocks do shareholders of TCR2 Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that TCR2 Therapeutics investors own include Digital Turbine (APPS), CrowdStrike (CRWD), Okta (OKTA), Vuzix (VUZI) and SoFi Technologies (SOFI).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/27/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TCRR
• CIK: 1750019
• Web: www.tcr2.com
• Phone: (617) 949-5200
• Fax: N/A
• Employees: 137
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($4.20)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$151.82 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -97.81%
• Return on Assets: -69.35%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.96
• Quick Ratio: 2.96

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.58 per share
• Price / Book: 0.57

Miscellaneous

• Outstanding Shares: 39,260,000
• Free Float: 29,443,000
• Market Cap: $58.10 million
• Optionable: Not Optionable
• Beta: 1.95